Table 2.
Selective ongoing clinical trials of combination immunotherapy agents in advanced hepatocellular carcinoma.
| Targeted Pathways | Agents Evaluated | Clinical Trial Registration Number |
|---|---|---|
| CTLA-4 + PD-1 | Nivolumab + ipilimumab | NCT03203304 |
| NCT03222076 | ||
| GM-CSF-armed oncolytic virus + PD-1 | PexaVec + Nivolumab | NCT03071094 |
| Tumor infiltrating lymphocytes + PD-1 | Tumor infiltrating lymphocytes + pembrolizumab | NCT01174121 |
| PD-1 + tyrosine kinase inhibitor | Pembrolizumab + regorafenib | NCT03347292 |
| Pembrolizumab + lenvatinib | NCT03006926 | |
| Nivolumab + cabozantinib | NCT03299946 | |
| Nivolumab ± lenvatinib | NCT03418922 | |
| Nivolumab + sorafenib | NCT03439891 | |
| Pembrolizumab + sorafenib | NCT03211416 | |
| PD-L1 + tyrosine kinase inhibitor | Avelumab + regorafenib | NCT03475953 |
| Avelumab + axitinib | NCT03289533 | |
| PD-1 + anti-VEGF agents | Nivolumab + bevacizumab | NCT03382886 |
| PD-L1 + anti-VEGF agents | Atezolizumab + bevacizumab | NCT02715531 |
| Atezolizumab + bevacizumab vs. sorafenib | NCT03434379 | |
| CTLA-4, PD-1, anti-OX40 antibody | INCAGN01949 + ipilimumab vs. | NCT03241173 |
| INCAGN01949 + nivolumab vs. | ||
| INCAGN01949 + nivolumab + ipilimumab |
CTLA4: cytotoxic T-lymphocyte-associated protein 4; PD-1: Programmed cell death protein-1; GM-CSF: Granulocyte monocyte-colony stimulating factor; PD-L1: Programmed cell death ligand-1; VEGF: Vascular endothelial growth factor.